Molecular biology

ROSALIND, HELiXrUS and Geninus Partner to Bring Powerful New Single Cell Analysis Services to Cancer Researchers

Thursday, April 15, 2021 - 1:01pm

It allows the direct measurement of gene expression and genetic alteration at scale with single cell resolution to quantify intracellular heterogeneity and characterize cell types, states, and cellular transition dynamics.

Key Points: 
  • It allows the direct measurement of gene expression and genetic alteration at scale with single cell resolution to quantify intracellular heterogeneity and characterize cell types, states, and cellular transition dynamics.
  • The service includes support for Single Cell Gene Expression, Single Cell Immune Profiling, Single Nucleus Gene Expression, Single Cell Multiome ATAC, and Spatial Gene Expression (Visium).\n\xe2\x80\x9cWe are thrilled to support Geninus in providing a world-class Single Cell Analysis experience for their customers while simultaneously enabling real-time collaboration within an advanced multi-omic discovery platform,\xe2\x80\x9d said Tim Wesselman, CEO of ROSALIND.
  • Geninus currently offers the tumor genome profiling platform CancerSCAN\xc2\xae, liquid biopsy-based LiquidSCAN\xc2\xae, and single cell RNA sequencing-based Celinus\xe2\x84\xa2 for serving the needs of clinicians, academic researchers, and pharmaceutical companies.
  • Until now, bioinformatic analysis has been one of the biggest bottlenecks of fully understanding and completing single cell research projects.

World CRISPR Gene Detection and Diagnostic Markets Report 2021-2025: Research, Clinical Lab, Consumer, Public Service & Other with Executive and Consultant Guides - ResearchAndMarkets.com

Wednesday, April 14, 2021 - 2:46pm

b'The "CRISPR Gene Detection and Diagnostic Markets by Research, Clinical Lab, Consumer, Public Service & Other with Executive and Consultant Guides - 2021 to 2025" report has been added to ResearchAndMarkets.com\'s offering.\nThe market has just gotten started with a handful of small startup companies.

Key Points: 
  • b'The "CRISPR Gene Detection and Diagnostic Markets by Research, Clinical Lab, Consumer, Public Service & Other with Executive and Consultant Guides - 2021 to 2025" report has been added to ResearchAndMarkets.com\'s offering.\nThe market has just gotten started with a handful of small startup companies.
  • Expect the big players to start taking notice.\nCRISPR is not just about changing genes.
  • CRISPR identifies unique genetic material instantly, accurately and cheaply.
  • A new COVID test is already available.\nWill this disruptive technology change the world of In Vitro Diagnostics?

Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date

Wednesday, April 14, 2021 - 1:05pm

(Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that since the Company began offering SARS-CoV-2 testing services in June 2020, it has now received more than 350,000 samples for testing.

Key Points: 
  • (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that since the Company began offering SARS-CoV-2 testing services in June 2020, it has now received more than 350,000 samples for testing.
  • Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
  • The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release.
  • We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.

StrideBio Announces a Multi-technology License and Master SRA with Duke University to Advance Next-generation Gene Therapies

Wednesday, April 14, 2021 - 12:05pm

b'StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV)-based gene therapies, today announced the signing of a multi-technology collaboration with Duke University that will enable novel next-generation gene therapies against a broad range of disorders.

Key Points: 
  • b'StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV)-based gene therapies, today announced the signing of a multi-technology collaboration with Duke University that will enable novel next-generation gene therapies against a broad range of disorders.
  • In addition, StrideBio has licensed exclusive rights covering a novel use of IgG-degrading enzyme IdeZ to clear neutralizing antibodies in conjunction with AAV gene therapy administration.
  • Our proprietary structure-inspired adeno-associated viral (AAV) vector engineering platform (STRIVE\xe2\x84\xa2) creates unique and differentiated capsids that overcome current limitations of first-generation gene therapies.
  • Combined with our genetic construct design expertise and in-house manufacturing capability at a 1000L scale, we are well positioned to advance novel best-in-class AAV gene therapies.

Aldevron Expands Commercial Leadership Team With Addition of Two Industry Veterans

Wednesday, April 14, 2021 - 12:30pm

b'Aldevron, the world\xe2\x80\x99s leading biomanufacturer of plasmid DNA, mRNA and proteins, is expanding its commercial leadership with the addition of Beth Thompson-Webb as Chief Commercial Officer and Todd Howren as Vice President of Sales.\nThis press release features multimedia.

Key Points: 
  • b'Aldevron, the world\xe2\x80\x99s leading biomanufacturer of plasmid DNA, mRNA and proteins, is expanding its commercial leadership with the addition of Beth Thompson-Webb as Chief Commercial Officer and Todd Howren as Vice President of Sales.\nThis press release features multimedia.
  • Under her leadership, the business experienced exceptional year over year growth and was recognized as the fastest growing and highest profile business within GE Healthcare Life Sciences.
  • Before joining Aldevron, Howren served as Vice President, Global Commercial Operations, Life Sciences Division at Meridian Bioscience.
  • The Company continues to support thousands of clients around the globe who require plasmids, proteins, and mRNA for research, clinical, and commercial applications.

Eurofins Covid Testing Services Ltd (ECTS) Supports Reopening UK Travel by Making PCR Testing Affordable for All

Tuesday, April 13, 2021 - 4:45pm

b'Eurofins Covid Testing Services Ltd (ECTS) recognises the importance of testing in the fight against COVID-19.

Key Points: 
  • b'Eurofins Covid Testing Services Ltd (ECTS) recognises the importance of testing in the fight against COVID-19.
  • Only the PCR test can provide the accuracy, reliability and variant tracking required to ensure the continued safety of everyone in the UK and whilst travelling.\nECTS wants to support the airline, travel and tourism industries and facilitate travel for all by removing the barrier of expensive testing.
  • ECTS has therefore recently made significant investments in technology and automation to be able to drastically reduce the price of test-at-home PCR kits to just \xc2\xa344.90, providing the UK\xe2\x80\x99s lowest cost option for both Test-To-Depart and Test-To-Release.
  • With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins\xe2\x80\x99 companies offer a portfolio of over 200,000 analytical methods.\nEurofins Shares are listed on Euronext Paris Stock Exchange.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210413005843/en/\n'

n-Lorem Foundation, ChemGenes Announce Collaboration to Support Manufacturing of Individualized Treatments for Patients with Ultra-Rare Diseases

Tuesday, April 13, 2021 - 1:00pm

\xe2\x80\x9cChemGenes joins Ionis Pharmaceuticals, Biogen, Ultragenyx Pharmaceutical, Charles River Labs, Covance by Labcorp, and Korea Institute of Toxicology (KIT) as industry partners supporting our efforts at n-Lorem.

Key Points: 
  • \xe2\x80\x9cChemGenes joins Ionis Pharmaceuticals, Biogen, Ultragenyx Pharmaceutical, Charles River Labs, Covance by Labcorp, and Korea Institute of Toxicology (KIT) as industry partners supporting our efforts at n-Lorem.
  • We are very pleased to join n-Lorem in this endeavor as a donor and a collaborator,\xe2\x80\x9d said Dr. Suresh Srivastava, President, ChemGenes Corporation.
  • ASOs are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality.
  • We have consistently been a strong partner to researchers engaged in the field of DNA/RNA synthesis for 40 years.

Global $49.99 Bn Genomics Market Forecast to 2027 - COVID-19 Impact and Analysis by Technology, Product & Service, Application, and End User and Geography - ResearchAndMarkets.com

Monday, April 12, 2021 - 3:55pm

b'The "Genomics Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Technology, Product & Service, Application, and End User and Geography" report has been added to ResearchAndMarkets.com\'s offering.\nGenomics Market was valued at US$ 19,084.74 million in 2019 and is projected to reach US$ 49,996.15 million by 2027; it is expected to grow at a CAGR of 13.1% from 2020 to 2027.\nBased on technology, the genomics market is segmented into sequencing, microarray, PCR, nucleic acid extraction and purification, and others.

Key Points: 
  • b'The "Genomics Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Technology, Product & Service, Application, and End User and Geography" report has been added to ResearchAndMarkets.com\'s offering.\nGenomics Market was valued at US$ 19,084.74 million in 2019 and is projected to reach US$ 49,996.15 million by 2027; it is expected to grow at a CAGR of 13.1% from 2020 to 2027.\nBased on technology, the genomics market is segmented into sequencing, microarray, PCR, nucleic acid extraction and purification, and others.
  • The sequencing segment held the largest share of the market in 2019.
  • The market growth for this segment is ascribed to its growing applications in medical, biotechnology, agriculture, diagnostics, and DNA Sequencing.\nAlso, increasing government genome sequencing programs, declining sequencing cost, and genomics studies.
  • However, the market for microarray segment is expected to grow at the fastest rate during the coming years.\nThe growth of the genomics market is attributed to the increasing prevalence of chronic diseases, declining cost of sequencing procedures, and growing funding for genomics.\nHowever, the lack of skilled professionals hinders the growth of this market.

FDA Authorizes First Single-Use, PCR Quality Over the Counter (OTC) LUCIRA CHECK IT™ COVID-19 At-Home Test. Available Now.

Monday, April 12, 2021 - 12:00pm

View the full release here: https://www.businesswire.com/news/home/20210412005361/en/\nThe LUCIRA CHECK IT\xe2\x84\xa2 test kit provides PCR quality, COVID-19 results in 30 minutes or less in the comfort of home.

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210412005361/en/\nThe LUCIRA CHECK IT\xe2\x84\xa2 test kit provides PCR quality, COVID-19 results in 30 minutes or less in the comfort of home.
  • OTC clearance dramatically expands the availability of this highly accurate test.\nEach single-use test kit contains everything needed to conduct one COVID-19 test.
  • It can detect a positive result in as few as 11 minutes or confirm a negative result within 30 minutes.
  • Our goal was to produce an easy-to-use test that provides PCR quality accuracy in a portable, intuitive, anytime, anywhere format,\xe2\x80\x9d said Lucira CEO Erik Engelson.

Global Whole Genome and Exome Sequencing Markets 2021-2025: COVID Pandemic Drives Overnight Global Growth in Pathogen Sequencing - A New Industry Emerges

Thursday, April 15, 2021 - 2:00pm

b'DUBLIN, April 15, 2021 /PRNewswire/ -- The "Whole Genome and Exome Sequencing Markets by Research, Clinical, Tumor, Pathogen, Agribio & Consumer with Executive and Consultant Guides.

Key Points: 
  • b'DUBLIN, April 15, 2021 /PRNewswire/ -- The "Whole Genome and Exome Sequencing Markets by Research, Clinical, Tumor, Pathogen, Agribio & Consumer with Executive and Consultant Guides.
  • (Including the Whole Genome Sequence of Sars-Cov-2) 2021 to 2025" report has been added to ResearchAndMarkets.com\'s offering.\nThe COVID Pandemic has created a surge in Whole Genome Sequencing of Pathogens but cancer-related activity has suffered.\nFind out all about it in the comprehensive report of Whole Genome Sequencing.
  • The complete genome of the COVID virus is included as an example of the work being done.\nWill all newborns receive Whole Genome Sequencing at birth?
  • Where are the over 800 locations that have high throughput devices?\nA plummeting of costs for Whole Genome Sequencing is creating a gold rush for market players.